Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

MALT Lymphoma Clinical Trial

Official title:

Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00923663
• Other study ID #: LEN-MALT
• Status: Unknown status
• Phase: Phase 2
• First received: June 17, 2009
• Last updated: September 27, 2010
• Start date: July 2009
• Est. completion date: June 2011

Study information

• Verified date: September 2010
• Source: Medical University of Vienna
• Contact: Markus Raderer, MD
• Phone: +43-1-40400
• Email: markus.raderer[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).

Description:

The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma.

The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 16
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with histologically confirmed MALT lymphoma with measurable disease (stage I
• IV)

• With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma

• Age > 18 years

• Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2

• Must be capable of understanding the purpose of the study and have given written informed consent

Exclusion Criteria:

• Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component

• Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide

• History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years

• Major surgery, other than diagnostic surgery, within the last 4 weeks

• Evidence of CNS involvement

• A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs

• Severe peripheral polyneuropathy

• Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months

• Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) < 1.0 x 109/L

• Patients with active opportunistic infections

• Pregnancy

• Uncontrolled diabetes mellitus

• Preexisting thromboembolic events at start of study

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• MALT Lymphoma

Intervention

Drug:
• Lenalidomide
25 mg Lenalidomide p.o. daily for 21 days

Locations

Country	Name	City	State
Austria	Dept of Internal Medicine	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of objective responses induced by Lenalidomide		24 months
Secondary	Time to progression		24 months